Results 101 to 110 of about 8,387 (243)

Central Beneficial Effects of Trimetazidine on Psychomotor Performance in Normal Healthy Volunteers

Advanced Biomedical Research, 2017
Background: Trimetazidine is a fatty oxidation inhibitor, leading to shifting of energy substrate from fatty acid oxidation toward glucose oxidation that leads to the reduction of oxygen requirement.
Hayder M Al-Kuraishy, Ali I Al-Gareeb
doaj   +1 more source

Combination Therapy With Beta‐Blockers and Angiotensin‐Converting Enzyme Inhibitors for Cardiovascular Diseases: Focus on Bisoprolol/Ramipril

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Patients with hypertension, especially when complicated by cardiovascular disease (CVD) and/or comorbidities, require long‐term treatment with a combination of antihypertensive drugs, which often gives rise to complex drug regimens. Dual‐agent combination antihypertensive therapy is recommended in most patients with hypertension, and where available, a
Agostino Virdis, Irfan Ahmad
wiley   +1 more source

Trimetazidine exerts protection against increasing current electroshock seizure test in mice [PDF]

, 2010
Trimetazidine, a novel anti-ischemic agent, is used in the therapy of angina, vertigo and chorioretinal diseases. It has also been examined for its effect on nociception, inflammation and neuroprotection in various animal models.
Bharal, Nidhi, Mediratta, Pramod Kumari, Jain, Seema, Sharma, Krishna Kishore   +3 more
core   +1 more source

Treatment with trimetazidine dihydrochloride and lung cancer survival: Implications on metabolic re-programming.

Lung Cancer
BACKGROUND Metabolic re-wiring with preferential fatty acid oxidation has been observed in lung cancer cells. Whether the use of trimetazidine, an anti-anginal agent that inhibits fatty acid oxidation, alters clinical outcomes in ischemic heart disease ...
Y. Chan, Yuen-Ting Cheng, Chun-Fun Sin, E. S. Ma, Stephen T. S. Lam, Shiu Lun Au Yeung, B. Cheung, C. Ho, Kai-Hang Yiu, Hung-Fat Tse   +9 more
semanticscholar   +1 more source

An adolescent hospitalised after polysubstance abuse: A case report

General Psychiatry, Volume 39, Issue 3, June 2026.
Haifeng Zhang, Jialong Yi, Xin Yu
wiley   +1 more source

Epicardial Lipomatosis as a Cause of Constrictive Pericarditis

Case Reports in Cardiology, Volume 2026, Issue 1, 2026.
Epicardial lipomatosis is a rare cause of constrictive pericarditis. There is a paucity of literature on the condition, and it is possible that it may be missed in contemporary clinical practice. Herein, we report two patients with epicardial lipomatosis who presented with traditional cardiovascular risk factors.
Punam Ajay Raval, John Otieno Odhiambo, Kevin Ombati, Barbara Karau, Leonard Mzee Ngunga, Satabdi Datta Choudhury   +5 more
wiley   +1 more source

Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy – Six months follow-up result

Indian Heart Journal, 2016
Background: Ischemic cardiomyopathy is a growing burden in third world countries. So far, benefits of trimetazidine in this group of patients have been suggested by clinical trials mainly conducted in Europe.
A. Momen, M. Ali, P.K. Karmakar, M.Z. Ali, A. Haque, M.R. Khan, M.I. Khalil, M.S. Hossain, R.M. Huda, M.N. Goni   +9 more
doaj   +1 more source

Diabetes Mellitus Duration and Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention: A Prospective Cohort Study

International Journal of Vascular Medicine, Volume 2026, Issue 1, 2026.
Objective This study is aimed at evaluating the impact of Type 2 diabetes mellitus (T2DM) duration on major adverse cardiovascular events (MACEs) after percutaneous coronary intervention (PCI). Methods A single‐center prospective cohort study was conducted in which 465 T2DM patients undergoing PCI and completing the 1‐year follow‐up were enrolled ...
Ayesha Tariq, Zohra Bhatti, Amer. H. Khan, Madeeha Laghari, Bandeh Ali Talpur, Muhammad Aamir, Khalid Hussain, Baohui Xu   +7 more
wiley   +1 more source

ISCHEMIC SYNDROMES AND CYTOPROTECTION (TRIMETAZIDINE)

, 2001
Ischemic syndromes and cytoprotection (trimetazidine)
A. A. Gorbachenkov, V. V. Hobot
core  

Metabolic modulators in cardioprotection: A focus on trimetazidine [PDF]

Cardiovascular diseases remain a significant health burden worldwide, necessitating the development of effective cardioprotective strategies. Central to this pursuit is the recognition of metabolic dysregulation as a key contributor to the pathogenesis ...
Du Qingyou
core   +2 more sources